Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.

Jose Garrido Mesa Kate Adams Julio Juan Gálvez Peralta Natividad Garrido-Mesa

Published in: Expert opinion on investigational drugs (2022)

The benefits of their multi-target pharmacology and their safety profile overcome the limitations, such as antibiotic activity and low commercial interest. Immunomodulatory tetracyclines and novel chemically modified non-antibiotic tetracyclines have therapeutic potential. Further drug repurposing studies in ARDS and severe COVID-19 are necessary.

Keyphrases

acute respiratory distress syndrome
coronavirus disease
extracorporeal membrane oxygenation
sars cov
mechanical ventilation
early onset
drug induced
respiratory syndrome coronavirus
case control
adverse drug
electronic health record